Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease


1 National TSE Reference Center, Department of Neurology, Georg-August University Goettingen, Goettingen, Germany
2 Department of Neuroradiology, Georg-August University Goettingen, Goettingen, Germany
3 CJD Surveillance Unit, Western General Hospital, Edinburgh, UK
4 Departamento de Neuropatologia, Centro de Referencia de Encefalopatias Espóngiformes Transmisibles, Instituto de Investigaciones Neurologicas/FLENI Montan˜eses 2325 C1428AQK, Buenos Aires, Argentina
5 Istituto Superiore di Sanitá, Department of Cell Biology and Neurosciences, Roma, Italy
6 Genetic Epidemiology Unit, Department of Epidemiology, Biostatistics and Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
7 INSERM UMR 975, Hôpital de la Salpêtrière Cellule Nationale de référence des maladies de Creutzfeldt-Jakob Paris, F-75013, France
8 Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, the University of Melbourne, Parkville, Australia 3010
9 Creutzfeldt-Jakob Disease Surveillance System, Prion Diseases Program, Public Health Agency of Canada, Ottawa, Canada
10 Division of Neurology, University Medical Center and Gerontopsychiatric Unit, University Psychiatric Hospital, SI-1000 Ljubljana, Slovenia
11 Department of Neurology, Laboratory of Neuropathology, Institute of Molecular Medicine, Hospital de Santa Maria, Lisbon Faculty of Medicine, Lisbon, Portugal
12 Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland
13 Clinic Director, Mercy Private Radiology, Grey st, East Melbourne, 3002, Australia
14 Laboratory of Neurobiology, Department of Neurology, Born Bunge Institute, University of Antwerp, Belgium
15 Fundación ‘Marqués de Valdecilla’ IFIMAV and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Santander, Spain

Corresponding author: Inga Zerr, MD, National TSE Reference Center, Department of Neurology, Georg-August University Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany
E-mail: epicjd@med.uni-goettingen.de

Several molecular subtypes of sporadic Creutzfeldt-Jakob disease have been identified and electroencephalogram and cerebrospinal fluid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype. In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. Magnetic resonance imaging signal alterations correlate with distinct sporadic Creutzfeldt-Jakob disease molecular subtypes and thus might contribute to the earlier identification of the whole spectrum of sporadic Creutzfeldt-Jakob disease cases. This multi-centre international study aimed to provide a rationale for the amendment of the clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Patients with sporadic Creutzfeldt–Jakob disease and fluid attenuated inversion recovery or diffusion-weight imaging were recruited from 12 countries. Patients
Introduction

Sporadic CJD (sCJD) is a transmissible neurodegenerative disorder with a fatal outcome. Clinical diagnostic criteria for sCJD were first formulated 30 years ago, using a combination of distinctive clinical features and best available auxiliary paraclinical investigations, which at that time was electroencephalography (EEG) (Masters et al., 1979). In recent years, there has been progress in developing other specialist investigations, including useful surrogate biomarkers in the cerebrospinal fluid (CSF), and clinical diagnostic criteria have been amended (Zerr et al., 2000a; Collins et al., 2006).

A series of recent publications has dealt with the clinical and pathological phenotypes and heterogeneity in sCJD (Parchi et al., 1999; Gambetti et al., 2003; Castellani et al., 2004; Collins et al., 2006; Sanchez-Juan et al., 2006). It has become apparent that a multimodal approach may be necessary if detection of the entire phenotypic spectrum of sCJD is to be achieved (Zerr et al., 2000b). Whereas some classical molecular subtypes such as the MM1 subtype frequently display periodic sharp and slow wave complexes in the EEG, the other five molecular subtypes are negative with this investigation (Parchi et al., 1999; Castellani et al., 2004; Collins et al., 2006). Utilizing CSF 14-3-3 protein detection provides a higher sensitivity, including less typical subtypes of sCJD such as VV1 and VV2 subtypes (Collins et al., 2006; Sanchez-Juan et al., 2006; Geschwind et al., 2009). However, even for CSF 14-3-3 protein detection with an overall sensitivity of 85%–95%, biological variables modify the test results and cases with longer duration or younger age at onset may be missed by this investigation (Castellani et al., 2004; Sanchez-Juan et al., 2006).

Acknowledging the limitations of the clinical criteria, the search for additional sCJD diagnostic investigations has continued. Magnetic resonance imaging (MRI) has become increasingly important in the clinical diagnosis of sCJD. The use of sensitive fluid attenuated inversion recovery (FLAIR) and diffusion-weight imaging (DWI) sequences allows the detection of basal ganglia hyperintensity and signal increase in other brain regions (Satoh et al., 2007; Tschampa et al., 2007; Fujita et al., 2008; Galanaud et al., 2008; Meissner et al., 2008). Characteristic MRI lesion patterns corresponding to individual CJD subtypes have been reported (Meissner et al., 2009). As MRI findings, even from early in the illness, are proving valuable in the evaluation of suspected sCJD patients, both by excluding other disorders and by demonstrating features considered typical of human prion disease (Geschwind et al., 2009), we undertook a systematic multi-centre international collaborative study to analyse the value of MRI lesion patterns in comparison to CSF biomarker 14-3-3 and periodic sharp wave complexes in the EEG in terms of test sensitivity and specificity.

Material and Methods

Patients

Cases were included from twelve countries (Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Portugal, Slovenia, Switzerland and United Kingdom) according to the following criteria: (i) CJD diagnosis confirmed by brain pathology (definite cases) or fulfilling accepted case definition criteria for ‘probable’ sCJD (data used for a separate set of analyses); (ii) molecular subtype determined by codon 129 genotyping (MM, MV or VV) and western blot analysis of brain pathogenic prion protein (PrPSc) type (1 or 2) (corresponding to MM1, MM2, MV1, MV2, VV1 and VV2 subtype) (Parchi et al., 1996, 1999); and (iii) available FLAIR or DWI MRI of the brain.

Controls

Controls were included according to the following criteria: (i) cases in which the diagnosis of sCJD was suspected (patients classified at least as
probable or possible CJD) but excluded on follow up by clinical investigations (improvement or recovery, inflammatory CSF findings, other diagnosis) or at autopsy; and (ii) available FLAIR or DWI brain MRI.

Codon 129 status was determined either as part of genotyping of the entire prion protein gene (PRNP) open reading frame or by restriction fragment length polymorphism analysis (Collins et al., 2006). Genetic CJD (causal mutations found in prionprotein gene), iatrogenic and variant CJD cases were excluded.

EEG (periodic sharp wave complexes) findings were also ascertained. The CSF 14-3-3 immunoassays were performed using western blotting as previously reported (Zerr et al., 2000a) and the conformity of test methods and interpretation of results was confirmed by a blinded sample exchange programme between laboratories (Sanchez-Juan et al., 2006).

The study comprised 436 sCJD patients who died between April 1998 and March 2007, and 141 controls: 32 (5.5%) from Argentina, 15 (2.6%) from Australia, 35 (6.1%) from Belgium, 9 (1.6%) from Canada, 16 (2.8%) from France, 328 (56.8%) from Germany, 32 (5.5%) from Italy, 17 (2.9%) from Netherlands, 7 (1.2%) from Portugal, 4 (0.7%) from Slovenia, 7 (1.2%) from Switzerland and 75 (13.0%) from UK.

MRI data

The magnetic resonance images were performed as routine clinical diagnostic studies and were collected from various hospitals in the framework of epidemiological studies as reported elsewhere (Meissner et al., 2009).

The majority of the scans were available as hardcopy. If serial MRIs were available, the first examination was used for the analysis. All scans were assessed by at least one neuroradiologist (K.K., D.S., C.R., P.S. or D.C.) aware that sCJD was a differential diagnostic possibility but blinded to the final diagnosis. All neuroradiologists assessed a small MRI series for the estimation of the inter-observer agreement. The intra reader concordance was high: 93.3%, $\kappa = 0.64$ ($P < 0.001$). Inter-rater concordance was 89%, $\kappa = 0.61$ ($P < 0.001$) and 82%, $\kappa = 0.62$ ($P < 0.001$) (which is high agreement) or 75.4%, $\kappa = 0.50$ ($P < 0.001$) and 76%, $\kappa = 0.45$ ($P < 0.001$) (moderate agreement).

A standardized protocol was used which included seven cerebral cortex regions (specifically the cingulate gyri, insular regions and hippocampi, as well as the remaining frontal, parietal and temporal lobes and the occipital lobes), basal ganglia (caudate nucleus, putamen, globus pallidus), thalamus (anterolateral nuclei, mediodorsal nuclei, pulvinar) and cerebellar cortex. For the thalamus, the presence or absence of a ‘pulvinar sign’ with extension into the antero-medial thalamus underscoring the ‘hockey stick sign’ was also rated (hyperintensity of the pulvinar relative to the anterior putamen) (Collie et al., 2003). The cerebral regions were assessed as hyperintense in relation to isointense cortex areas. As most MRI data were available as hardcopy only, the grade of hyperintensity was not quantified. For each MRI examination, T2-weighted (T2-w) images were evaluated first, followed by FLAIR and DWI. For further analyses, only FLAIR and DWI were considered e.g. only the most sensitive sequences, FLAIR and DWI (Kallenberg et al., 2006), were considered. Proton-density-weighted scans and apparent diffusion coefficient maps were less commonly used and not included in this study. Areas of hyperintensity were scored separately for each sequence. The quality of the complete MRI examination was graded from 1 to 6 (1 = excellent, 2 = good, 3 = average, 4 = sufficient, 5 = insufficient, 6 = poor). Scans graded higher than 4 were considered as non-diagnostic (mainly due to motion artefacts) and excluded from the study.

Statistical analysis

Descriptive statistics were reported for sCJD and control patients; $\chi^2$-test and the non-parametric Mann-Whitney test were used to assess differences between categorical and continuous variables.

The goal of our study was to identify the best combination of radiological findings and MRI sequences to discriminate between sCJD and non-sCJD patients. In order to do this we compared the results of visual assessments of brain MRI scans in cases and controls. We considered a brain region as affected when a high signal was found in either FLAIR or DWI MRI sequences. We calculated sensitivity [the percentage of scans considered as characteristic (positive) of sCJD in cases] and specificity [the percentage of scans considered as not characteristic (negative) of sCJD in controls] for several criteria patterns involving different combinations of affected regions and MRI sequences. We also calculated diagnostic odds ratios—the ratio of the odds of positivity in sCJD cases relative to the odds of positivity in the controls—to assess which combinations of criteria patterns yielded better test discriminatory performance; 95% confidence intervals of the diagnostic odds ratios were estimated by the exact method.

Inter-reader agreement for brain MRI scan visual assessment (normal or affected) was calculated, using Cohen’s $\kappa$ coefficient and Concordance Index, for all explored areas included in the standardized protocol. Concordance Index is the percentage of agreement between readers and the $\kappa$ coefficient shows the difference in agreement, from chance, between them; thus a $\kappa$-value of 0 means no different from chance and 1 is perfect agreement.

Ethics

The study was done in accordance with the current revision of the Declaration of Helsinki and the Good Clinical Practice: Consolidated Guideline approved by the International Conference on Harmonization and applicable to national and local laws and regulations. For each participating site, the study protocol and all amendments were approved by an institutional review board or independent ethics committee. All patients and their caregivers gave written informed consent.

Results

Patients

In total, MRI scans were available for 436 patients with sCJD and 141 controls.

FLAIR sequences were available in 379 cases and in 128 controls, DWI in 258 cases and 81 controls. Both sequences were available in 201 cases and 68 controls. The median time from onset to MRI was 2.7 months in sCJD cases and 6.7 months in controls. Patient characteristics are summarized in Table 1.

Definition of the criteria

In the first part of the study, we analysed which FLAIR and/or DWI MRI lesion pattern was characteristic for sCJD, regardless of molecular subtype. To achieve this, a stepwise analysis was performed: (i) selection of the cortical regions; (ii) combination cortical/subcortical areas; and (iii) definition of the best MRI sequence (FLAIR/DWI).
Selection of cortical regions

In this part of the study, we analysed the frequency of high signal detection in each cortical region for cases and controls and stratified the data by the MRI technique used (FLAIR or DWI, Table 2). As the result of this analysis, we selected three regions with the optimum sensitivity and specificity data, irrespective of MRI technique used. The three areas with the highest values for diagnostic accuracy were the parietal, occipital and temporal cortical regions. The other cortical brain regions such as cingulate gyrus, insular cortex or hippocampus were either non-discriminatory between cases and controls, had low specificity and, in addition to this, found low inter reader agreement, as reported before (Krasnianski et al., 2008).

Combination of cortical and subcortical areas

Various combinations of high signal intensity were analysed in the three selected cortical (parietal, occipital and temporal) and subcortical regions. The results are given in Table 3. For FLAIR and DWI, the best results were obtained when two or more regions (either temporal, parietal, occipital) displayed a high signal in the MRI. The poorest specificity was obtained when MRI scans were considered positive when only one cerebral cortical region showed a high signal; therefore, those patterns were excluded for further analysis. For subcortical areas, the optimum diagnostic accuracy was obtained when a high signal increase was observed in both the caudate nucleus and putamen simultaneously. DWI was generally more sensitive than FLAIR with a similar specificity for both sequences.

Further analyses determined the best possible combination of various cerebral cortical and subcortical high signal changes. The highest diagnostic accuracy was obtained by accepting either a combination of at least two cerebral cortical regions (temporal, occipital, parietal) showing increased signal or both the putamen and the caudate nucleus showing high signal intensity (Table 4).

Definition of the MRI sequence

After choosing the combination of either at least two cerebral cortical regions or both the putamen and caudate nucleus showing high signal as the optimal radiological pattern, we analysed which MRI pulse sequence or potential combination of sequences revealed the highest sensitivity and specificity. Both sequences achieved high diagnostic accuracy (Table 5). We calculated the data for other potential combinations, such as FLAIR and DWI positive, but the sensitivity achieved was only 54%.

In order to estimate the sensitivity and specificity of the combination FLAIR or DWI, we considered that patients with both pulse sequences available were most reliable, because including patients with only one sequence would result in a predominance of the ‘only FLAIR performed’ and a decrease in the sensitivity (Table 5), since FLAIR is less sensitive than DWI.

False-positive findings in the MRI

According to our criteria, 19 controls had positive findings on the MRI. Most of these suffered from an infectious or inflammatory disorder of the central nervous system (n = 9), like lymphocytic encephalitis, progressive multifocal leucencephalopathy, steroid responsive encephalitis associated with autoimmune thyroiditis (SREAT) or encephalitis of unknown origin. In other patients with a positive MRI, autopsy confirmed Alzheimer’s disease (n = 2), Dementia with Lewy bodies (n = 2), epilepsy (n = 2), intravascular lymphomatosis and mitochondrial cytopathy.
Two patients recovered and the diagnosis is not known. No distinctive MRI pattern could be detected for each disorder and the frequency of high signal abnormalities in cortical and subcortical areas was similar in all the diagnostic groups mentioned above.

**Table 3 Selection of cortical and subcortical areas**

<table>
<thead>
<tr>
<th>FLAIR Controls</th>
<th>Total sCJD cases</th>
<th>Definite sCJD cases</th>
<th>DWI Controls</th>
<th>Total sCJD cases</th>
<th>Definite sCJD cases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At least one cortical region</strong>&lt;sup&gt;a&lt;/sup&gt; affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>94 (73.4)</td>
<td>190 (50.1)</td>
<td>111 (48.1)</td>
<td>60 (74.1)</td>
<td>57 (22.1)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>34 (26.6)</td>
<td>189 (49.9)</td>
<td>120 (51.9)</td>
<td>21 (25.9)</td>
<td>201 (77.9)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>2.8 (1.5–4.0)</td>
<td>3.0 (1.6–4.4)</td>
<td>10.1 (4.3–15.9)</td>
<td>12.1 (4.4–19.9)</td>
<td></td>
</tr>
<tr>
<td><strong>At least two cortical regions</strong>&lt;sup&gt;a&lt;/sup&gt; affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>121 (94.5)</td>
<td>278 (73.4)</td>
<td>173 (74.9)</td>
<td>72 (88.9)</td>
<td>115 (44.6)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>7 (5.5)</td>
<td>101 (26.6)</td>
<td>58 (25.1)</td>
<td>9 (11.1)</td>
<td>143 (55.4)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>6.3 (1.3–11.3)</td>
<td>5.8 (1.1–10.5)</td>
<td>10.0 (2.6–17.3)</td>
<td>11.6 (2.7–20.5)</td>
<td></td>
</tr>
<tr>
<td><strong>More than three cortical regions</strong> affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>115 (89.8)</td>
<td>276 (72.8)</td>
<td>163 (70.6)</td>
<td>68 (84.0)</td>
<td>111 (43.0)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>10 (10.2)</td>
<td>103 (27.2)</td>
<td>68 (29.4)</td>
<td>13 (16.0)</td>
<td>147 (57.0)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>3.3 (1.3–5.3)</td>
<td>3.7 (1.3–6.1)</td>
<td>6.9 (2.5–11.4)</td>
<td>8.7 (2.8–14.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Putamen or caudatum affected</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>104 (81.3)</td>
<td>147 (38.8)</td>
<td>83 (35.9)</td>
<td>67 (82.7)</td>
<td>83 (32.2)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>24 (18.8)</td>
<td>232 (61.2)</td>
<td>148 (64.1)</td>
<td>14 (17.3)</td>
<td>175 (67.8)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>6.8 (3.5–10.2)</td>
<td>7.7 (3.7–11.7)</td>
<td>10.1 (3.7–16.5)</td>
<td>11.8 (3.8–19.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Both putamen and caudatum affected</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>120 (93.8)</td>
<td>223 (58.8)</td>
<td>135 (58.4)</td>
<td>76 (93.8)</td>
<td>133 (51.6)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>8 (6.3)</td>
<td>156 (41.2)</td>
<td>96 (41.6)</td>
<td>5 (6.2)</td>
<td>125 (48.4)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>10.5 (2.7–18.3)</td>
<td>10.7 (2.5–18.8)</td>
<td>14.3 (0.9–27.7)</td>
<td>15.2 (0.6–29.8)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Parietal–temporal–occipital; CI = confidence interval; s = sCJD cases.

<table>
<thead>
<tr>
<th>Table 4 Selection of cortical and subcortical areas best combination</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FLAIR Controls</td>
<td>Total sCJD cases</td>
<td>Definite sCJD cases</td>
<td>DWI Controls</td>
<td>Total sCJD cases</td>
<td>Definite sCJD cases</td>
</tr>
<tr>
<td>More than three cortical regions OR both Put. and NC affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>110 (85.9)</td>
<td>166 (43.8)</td>
<td>94 (40.7)</td>
<td>66 (81.5)</td>
<td>62 (24.0)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>18 (14.1)</td>
<td>213 (56.2)</td>
<td>137 (59.3)</td>
<td>15 (18.5)</td>
<td>196 (76.0)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>7.8 (3.6–12.1)</td>
<td>8.9 (3.9–13.9)</td>
<td>13.9 (5.2-22.7)</td>
<td>16.5 (5.2-27.8)</td>
<td></td>
</tr>
<tr>
<td>More than three cortical regions OR Put. OR NC affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>99 (77.3)</td>
<td>113 (29.8)</td>
<td>60 (26.0)</td>
<td>61 (75.3)</td>
<td>41 (15.9)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>29 (22.7)</td>
<td>266 (70.2)</td>
<td>171 (74.0)</td>
<td>20 (24.7)</td>
<td>217 (84.1)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>8.0 (4.3–11.8)</td>
<td>9.7 (4.8–14.7)</td>
<td>16.1 (6.4–25.9)</td>
<td>21.4 (6.5–36.2)</td>
<td></td>
</tr>
<tr>
<td>At least two cortical regions&lt;sup&gt;a&lt;/sup&gt; affected OR both Put. and NC affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>116 (90.6)</td>
<td>162 (42.7)</td>
<td>97 (42.0)</td>
<td>70 (86.4)</td>
<td>63 (24.4)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>12 (9.4)</td>
<td>217 (57.3)</td>
<td>134 (58.0)</td>
<td>11 (13.6)</td>
<td>195 (75.6)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>13.0 (4.8–21.1)</td>
<td>13.4 (4.7–22.0)</td>
<td>19.7 (6.0–33.4)</td>
<td>23.0 (5.9-40.0)</td>
<td></td>
</tr>
<tr>
<td>At least two cortical regions&lt;sup&gt;a&lt;/sup&gt; affected OR Put. OR NC affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>103 (80.5)</td>
<td>106 (28.0)</td>
<td>58 (25.1)</td>
<td>62 (76.5)</td>
<td>42 (16.3)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>25 (19.5)</td>
<td>273 (72.0)</td>
<td>173 (74.9)</td>
<td>19 (23.5)</td>
<td>216 (83.7)</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95% CI)</td>
<td>10.6 (5.4–15.8)</td>
<td>12.3 (5.8–18.8)</td>
<td>16.8 (6.5–27.0)</td>
<td>20.4 (6.3–34.4)</td>
<td></td>
</tr>
</tbody>
</table>

NC = nucleus caudatum; Put. = putamen.
<sup>a</sup> Parietal–temporal–occipital.

**Table 3** Selection of cortical and subcortical areas

**Table 4** Selection of cortical and subcortical areas best combination

**Modification of clinical criteria for sCJD**

Based on our results, we recommend modifying the current clinical diagnostic criteria for sCJD to include the detection of either

Two patients recovered and the diagnosis is not known. No distinctive MRI pattern could be detected for each disorder and the frequency of high signal abnormalities in cortical and subcortical areas was similar in all the diagnostic groups mentioned above.
hyperintensity in the basal ganglia (both caudate nucleus and putamen) or in at least two cortical regions (from either the temporal, parietal or occipital cerebral cortices) (Fig. 1). This implies that the detection of the specified high signal abnormalities in FLAIR or DWI MRI will be considered at the same level of diagnostic importance as periodic sharp wave complexes on the EEG or 14-3-3 protein detection in the CSF.

Comparative analysis of the EEG, CSF and MRI

In a subgroup of 214 definite CJD patients and 77 definite non-cases, we analysed the frequency of true-positive results in cases (sensitivity) and true-negative results in controls (specificity), in relation to the detection of periodic sharp wave complexes in the EEG, elevated CSF levels of 14-3-3 protein or MRI abnormalities. Diagnostic MRI abnormalities for sCJD, as defined by our analyses, were observed in 83% of such patients with a specificity of 83%. For CSF 14-3-3 protein detection, test sensitivity was 86% but specificity was 68%. EEG had the lowest sensitivity (44%) and highest specificity (92%). Details on comparative analyses of current and amended criteria are given in Table 6. The sensitivity of current criteria is 92%, the specificity 71%. Thus, 8% of sCJD patients are not covered by the World Health

### Table 5 Definition of MRI sequences for the pattern at least two cortical regions affected (parietal–temporal–occipital) or both putamen and nucleus caudatum affected

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>Total sCJD cases</th>
<th>Definite sCJD cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLAIR AND DWI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>64 (94.1)</td>
<td>92 (45.8)</td>
<td>55 (45.8)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>4 (5.9)</td>
<td>109 (54.2)</td>
<td>65 (54.2)</td>
</tr>
<tr>
<td>Total (n)</td>
<td>68</td>
<td>201</td>
<td>120</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95%CI)</td>
<td>19.0 (0.9–38.8)</td>
<td>18.9 (1.4–39.2)</td>
<td></td>
</tr>
<tr>
<td>FLAIR OR DWI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>122 (86.5)</td>
<td>133 (30.5)</td>
<td>75 (28.5)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>19 (13.5)</td>
<td>303 (69.5)</td>
<td>188 (71.5)</td>
</tr>
<tr>
<td>Total (n)</td>
<td>141</td>
<td>436</td>
<td>263</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95%CI)</td>
<td>14.6 (7.0–22.3)</td>
<td>16.1 (7.2–25.0)</td>
<td></td>
</tr>
<tr>
<td>FLAIR OR DWI a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (%)</td>
<td>56 (82.3)</td>
<td>38 (18.9)</td>
<td>21 (17.5)</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>12 (17.6)</td>
<td>163 (81.1)</td>
<td>99 (82.5)</td>
</tr>
<tr>
<td>Total (n)</td>
<td>68</td>
<td>201</td>
<td>120</td>
</tr>
<tr>
<td>Diagnostic odds ratio (95%CI)</td>
<td>20.0 (5.7–34.4)</td>
<td>22.0 (4.8–39.2)</td>
<td></td>
</tr>
</tbody>
</table>

a Only cases with both sequences available.

---

**I. clinical signs:**

1. dementia
2. cerebellar or visual
3. pyramidal or extrapyramidal
4. akinetic mutism

**II. tests:**

1. PSWCs in EEG
2. 14-3-3 detection in CSF (in patients with a disease duration of less than 2 year)
3. high signal abnormalities in caudate nucleus and putamen or at least two cortical regions (temporal-parietal-occipital) either in DWI or FLAIR

**Probable CJD**

two out of I and at least one out of II

**Possible CJD**

two out of I and duration less than 2 years

---

*Figure 1* MRI-CJD Consortium criteria for sporadic Creutzfeldt-Jakob disease.
Organization criteria. By inclusion of the MRI as an additional parameter for 'probable' CJD, the sensitivity of clinical criteria rises substantially to 98%, but specificity drops marginally.

Value of MRI in identification of various molecular sCJD subtypes

A comparative analysis of protein 14-3-3, EEG and MRI in a subset of CJD patients with data on pathogenic prion protein type and codon 129 genotype available is shown in Table 7. Currently used criteria improved the recognition of some of the less typical sCJD subtypes such as VV2. Amended criteria, as suggested here, are especially helpful for the rare and atypical subtypes such as MM2, MV1 and MV2. The latter may develop an atypical clinical syndrome and thus not be properly diagnosed on clinical grounds (Krasnianski et al., 2006a, b)

Discussion

This multi-centre collaborative study analysed findings from MRI scans in a large number of sCJD cases and controls; and has provided evidence that justifies the inclusion of defined MRI pattern in the clinical diagnostic criteria for sCJD. In a previous manuscript, we reported characteristic MRI patterns for each molecular CJD subtype (Meissner et al., 2009) and identified variables which allowed for the best discrimination between those subtypes. We chose the following radiological signs as predictors of sCJD subtypes: high signal in (i) more than three
cerebral cortical regions; (ii) hippocampus; (iii) any basal ganglia; (iv) thalamic nuclei; and (v) cerebellum. Multivariate analysis, including the five selected regions, was performed in order to allow independent assessment of these parameters and a specific MRI lesion pattern for each molecular disease subtype was identified (Meissner et al., 2009). Specificity of MRI changes was not addressed. Since the information on specificity is essential for an assessment of the true utility of MRI brain scan in the diagnosis of sCJD, we performed the current study.

In order to assess the sensitivity of MRI in the diagnosis of sCJD, we developed a set of variables which allowed the optimum discrimination between CJD and controls. In this analysis, we selected anatomical regions which have been demonstrated to be frequently affected (Meissner et al., 2009). The characteristic MRI lesion pattern, which allowed for the best discrimination between sCJD cases and controls was found to be high signal intensity in FLAIR or DWI in at least two cortical regions, or signal increase in the caudate nucleus and putamen. Based on these findings, we propose that the clinical diagnostic criteria for sCJD are amended to include MRI signal abnormalities as defined above (Fig. 1). The MRI findings will thus be equivalent to elevated levels of 14-3-3 proteins or periodic sharp and slow wave complexes in the EEG for the clinical diagnosis of probable sCJD.

With respect to current clinical tests for sCJD, the EEG was the first in vivo test to be used to support the clinical diagnosis of sCJD. However, the EEG has been shown to be positive in only a subset of sCJD patients, usually MM1 or MV1 cases. Typically, periodic sharp wave complexes are detected late in the disease and the median time to positive EEG is around 12 weeks. This corresponds to the terminal stages of the illness (Poser et al., 1999; Zerr et al., 2000a; Collins et al., 2006). A number of CSF biomarkers have been reported in sCJD, including 14-3-3, tau, S100b, neuron-specific enolase, phosphorylated tau and abeta, with the majority of available data relating to 14-3-3 and tau proteins (Sanchez-Juan et al., 2006). Both these biomarkers support the clinical CJD diagnosis with a sensitivity of 92% and specificity of 71% (Sanchez-Juan et al., 2006). However, a number of publications have indicated that low levels of these biomarkers are present in the CSF in some atypical CJD variants (Castellani et al., 2004; Sanchez-Juan et al., 2006; Gmitterová et al., 2008). Biological variables such as long disease duration, young age at onset, type 2 pathogenic prion protein and heterozygosity at codon 129 genotype of the PrP gene are all associated with low biomarker levels (Parchi et al., 1999; Zerr et al., 2000b; Castellani et al., 2004; Sanchez-Juan et al., 2006). This is in contrast with the results of MRI scans in some atypical and rare variants of sCJD, such as VV1 and MV2: in VV1 patients there is high signal in the cortical areas and normal signal in the basal ganglia, while in MV2 patients characteristic abnormalities are seen in the basal ganglia, putamen and thalamus (Meissner et al., 2005; Krasnianski et al., 2006b, 2008). Characteristic lesion patterns have recently been reported for patients with other molecular disease subtypes (Meissner et al., 2009) and the question was raised whether MRI brain scan might contribute to the improved diagnosis across sCJD subtypes (Tschampa et al., 2005; Meissner et al., 2009).

Table 7 shows the data on positive tests in a subgroup of patients with known molecular type. MRI findings are positive in 81% of sCJD patients. Sensitivity of the 14-3-3 test is 86% and significantly less for the EEG. By combination of all parameters, sensitivity is 98% and specificity of the criteria is 71%. Although the frequency and location of high signal intensities vary between subtypes, by amendment of clinical criteria, most molecular disease subtypes will be covered, including rare subtypes VV1 and MV2 (Table 7).

Our results indicate a high rate of agreement between identification of cortical parietal, temporal and occipital signal and basal ganglia involvement between five raters, even in a cohort of patients where MRI scans were acquired at different centres, with some modifications. These results suggest that MRI is a robust investigation in sCJD and qualifies as a potential biomarker for CJD.

A limitation of this study is the high number of sCJD cases as compared to controls. However, the gold standard for the validation of the clinical diagnostic criteria was the analysis of the subset of sCJD cases in which the diagnosis had been confirmed by neuropathology. In controls, only data from patients in which the diagnosis of CJD had been definitely excluded by neuropathology or in which there was a definite alternative clinical diagnosis, were used. This group included cases who recovered, cases with inflammatory CSF findings indicating an alternative diagnosis or a clinical course which excluded CJD as a diagnosis (Heinemann et al., 2007). In the context of a multi-centre MRI study on a rare disorder, achieving a high autopsy rate in non-cases is difficult and it would take many years to obtain a representative autopsy sample of non-cases at a similar rate to the sCJD cases. Epidemiological surveillance studies on rare disorders are person and cost intensive and a study with selected MRI scans on more than 300 cases and controls on a solely autopsic sample is unlikely to be feasible in the near future. However, in this study, we have achieved neuropathology confirmation in 40% of controls and in 60% of CJD patients.

Our analysis has shown that MRI findings may lead to false positive diagnosis in a small number of cases. This is an important issue for the accurate diagnosis of sCJD. Almost 50% of false positive findings on the MRI were associated with inflammatory conditions; the other diagnoses were Alzheimer’s disease and Dementia with Lewy bodies (Halk et al., 2000; Tschampa et al., 2001). Inflammatory conditions of the brain represent the most important differential diagnosis as there may be a possibility for treatment (Chang et al., 2007; Heinemann et al., 2007; Geschwind et al., 2008). In our patients, diagnoses included encephalitis of unknown origin and SREAT (Seipel et al., 1999). The latter diagnosis has been described previously as an important treatable condition in the differential diagnosis of CJD. The crucial question for the clinician is how to avoid the misinterpretation of tests and how to avoid missing a treatable condition in a patient with a rapid progressive dementia and focal neurological signs (Josephs et al., 2009). Thorough analysis of the cerebrospinal fluid for routine parameters such as cell count, protein and oligo-clonal bands (which are often positive in SREAT and other inflammatory conditions, but usually negative in CJD) may be helpful in diagnosis (Jacobi et al., 2005; Green et al., 2007). As other tests,
such as 14-3-3 and EEG, may also show ‘false-positive’ results in inflammatory conditions of the brain, accurate clinical diagnosis can be a major challenge. Thus, patients with ‘inflammatory’ abnormalities in the CSF such as pleocytosis, high elevated protein content and oligoclonal immunglobulin G should enter the diagnostic pathway for potentially treatable conditions (Vernino et al., 2007).

The time point at which the clinical diagnosis of sCJD is made may be very important if treatment strategies become available as any therapy will probably need to be started early if it is to be effective. The EEG has been shown to become positive usually only in the late stages of the disease. CSF biomarkers can become positive in the early disease stages, as shown in a cohort of patients with repeated lumbar punctures and multiple CSF tests (Sanchez-Juan et al., 2007). With MRI the question on when the typical changes appear is still unresolved because of the limited number of patients with multiple scans. However, there is a suggestion from the literature that MRI may become positive early in the disease (Young et al., 2005; Fujita et al., 2008; Galanaud et al., 2008; Hoshino et al., 2008). Further work will be needed to address this question.

In summary, our data show that basal ganglia and cortical hyperintensities represent the most frequent MRI findings in sCJD and are present in most cases. Characteristic brain MRI lesion patterns are helpful in establishing a diagnosis of sCJD and may help to identify atypical sporadic disease forms. This is the most comprehensive study on MRI findings in sCJD to date, and in combination with previous studies, provides firm evidence that brain MRI has a high sensitivity and specificity in the diagnosis of the disease.

Acknowledgements

This study was supported by grants from the German Federal Ministry of Education and Research (Brain imaging as an aid to determine molecular subtype in prion diseases, BMBF ARG07/008 and Forschungsnetz zur Verbesserung der Früh- und Differentialdiagnose der CJK und rasch progressiver Demenzen, BMBF 01 610 301 to I.Z.), by the Robert Koch-Institut through funds of the Federal Ministry of Health (grant no 1369-341), and by the Verein zur Förderung der Wissenschaft und Forschung am der Neurologischen Klinik Göttingen e.V. (to I.Z.)

Grants at national levels are reported below:

Argentina
FLENI-SECYT BID 802-OC-AR PID 98/027/BID 1728; OC-AR PID 2003/351; BMBF-MINCYT-ARG 10/008

We thank all the neurologists who contributed to CJD surveillance in Argentina and especially to Dr E.Meichtry - Moguillansky Clinic- Neuquén-Argentina for his continuous support.

Australia
The Australian National Creutzfeldt-Jakob disease Registry (ANCJDR) thanks Colin Masters, Alison Boyd, Genevieve Klug, Samantha Douglas, Christiane Stehmann and Amelia McGlade for their valuable contributions, as well as the families of CJD patients and their physicians for their generous support and assistance. The ANCJDR is funded by the Commonwealth Department of Health and Ageing.

Belgium
Fonds voor Wetenschappelijk Onderzoek; Born Bunge Institute.

Canada
The Canadian Creutzfeldt–Jakob Disease Surveillance System thanks the families of CJD patients and their physicians for participation in the study. Canadian Neuropathologists are acknowledged for their valuable contributions. All personnel of the Prion Diseases Program are thanked for their enthusiastic cooperation.

France
We thank all members of the French National Surveillance Network for Creutzfeldt–Jakob disease and all physicians for case notification and provision of clinical and pathological data and MRI scan.

Germany
This study was funded by Robert Koch-Institute through funds of the Federal Ministry of Health (grant no 1369-341). We thank physicians for case notification and provision of clinical and pathological data and MRI scans to the National TSE Surveillance Unit, Göttingen, Germany. We are grateful to Jolanthe Ehrlich for her technical assistance in the database management.

Italy
We thank neurologists and neurodiologists for case notification and provision of clinical and MRI scans, Dr Piero Parchi, Prof. Salvatore Monaco, Dr. Gianluigi Zanusso and Dr Carlo Buffa for the neuropathological evaluation and PrP western blot typing, Dr Sabina Capellari, Dr Daniele Imperiale, Dr Anna Poleggi, Dr Claudia Giannattasio and Mr Michele Equestre for genetic and CSF 14-3-3 analyses. This work was partially supported by the National Registry of CJD and related disorders of the Istituto Superiore di Sanità, Rome, Italy.

Slovenia
We thank all members of the national CJD surveillance group as well as all physicians involved in case notification and we are especially grateful to neuroradiologists for providing us with the MRI scans.

Spain
Fondo de Investigacion Sanitaria (grant PI080139).

Switzerland
We thank all referring physicians. The national Reference Center for Prion Diseases is funded by the Swiss federal Office of Public Health.

UK
The authors are grateful to neuroradiologists from throughout the UK for access to MRI scans. In part by the Department of Health
(121/7369); European Union (Network of Excellence FOOD CT 2004 056579 and ECDC: grant number ECD 607). The UK National CJD Surveillance Unit is funded by the Department of Health and the Scottish Executive Unit of Department of Health.

References


